Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation

      No studies have performed direct pairwise comparisons of the effectiveness and safety of warfarin and the new oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban. Using 2013 to 2014 claims from a 5% random sample of Medicare beneficiaries, we identified patients newly diagnosed with atrial fibrillation who initiated apixaban, dabigatran, rivaroxaban, warfarin, or no oral anticoagulation therapy in 2013 to 2014. Outcomes included the composite of ischemic stroke, systemic embolism (SE) and death, any bleeding event, gastrointestinal bleeding, intracranial bleeding, and treatment persistence. We constructed Cox proportional hazard models to compare outcomes between each pair of treatment groups. The composite risk of ischemic stroke, SE, and death was lower for NOACs than for warfarin: hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76 to 0.98 for apixaban; 0.73, 95% CI 0.63 to 0.86 for dabigatran; and 0.82, 95% CI 0.75 to 0.89 for rivaroxaban, all compared with warfarin. There were no differences in effectiveness across NOACs. The risk of any bleeding was lower with apixaban than with warfarin, but higher with rivaroxaban than with warfarin. Apixaban (HR 0.69, 95% CI 0.60 to 0.79) and dabigatran (HR 0.79, 95% CI 0.69 to 0.92) were associated with lower bleeding risk than rivaroxaban. Treatment persistence was highest for apixaban (82%), and lowest for dabigatran and warfarin (64%) (p value <0.001). Compared with warfarin, NOACs are more effective in preventing stroke but their risk of bleeding varies, with rivaroxaban having higher risk than warfarin. Altogether, apixaban had the most favorable effectiveness, safety, and persistence profile.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hernandez I.
        • Zhang Y.
        Comparing stroke and bleeding with rivaroxaban and dabigatran in atrial fibrillation: analysis of the US Medicare part D data.
        Am J Cardiovasc Drugs. 2017; 17: 37-47
        • Chan Y.H.
        • Kuo C.T.
        • Yeh Y.H.
        • Chang S.H.
        • Wu L.S.
        • Lee H.F.
        • Tu H.T.
        • See L.C.
        Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation.
        J Am Coll Cardiol. 2016; 68: 1389-1401
        • Noseworthy P.A.
        • Yao X.
        • Abraham N.S.
        • Sangaralingham L.R.
        • McBane R.D.
        • Shah N.D.
        Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation.
        Chest. 2016; 150: 1302-1312
        • Graham D.J.
        • Reichman M.E.
        • Wernecke M.
        • Hsueh Y.H.
        • Izem R.
        • Southworth M.R.
        • Wei Y.
        • Liao J.
        • Goulding M.R.
        • Mott K.
        • Chillarige Y.
        • MaCurdy T.E.
        • Worrall C.
        • Kelman J.A.
        Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation.
        JAMA Intern Med. 2016; 176: 1662-1671
        • Hernandez I.
        • Baik S.H.
        • Pinera A.
        • Zhang Y.
        Risk of bleeding with dabigatran in atrial fibrillation.
        JAMA Intern Med. 2015; 175: 18-24
        • Hernandez I.
        • Zhang Y.
        • Brooks M.M.
        • Chin P.K.
        • Saba S.
        Anticoagulation use and clinical outcomes following major bleeding on dabigatran or warfarin in atrial fibrillation.
        Stroke. 2017; 48: 159-166
        • Lip G.Y.
        • Nieuwlaat R.
        • Pisters R.
        • Lane D.A.
        • Crijns H.J.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation.
        Chest. 2010; 137: 263-272
        • Pisters R.
        • Lane D.A.
        • Nieuwlaat R.
        • de Vos C.B.
        • Crijns H.J.
        • Lip G.Y.
        A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
        Chest. 2010; 138: 1093-1100
        • Center for Medicare and Medicaid Services Chronic Conditions Data Warehouse
        27 chronic condition algorithm.
        (Available at:)
        • Hart R.G.
        • Pearce L.A.
        • Aguilar M.I.
        Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
        Ann Intern Med. 2007; 146: 857-867
        • Graham D.J.
        • Reichman M.E.
        • Wernecke M.
        • Zhang R.
        • Southworth M.R.
        • Levenson M.
        • Sheu T.C.
        • Mott K.
        • Goulding M.R.
        • Houstoun M.
        • MaCurdy T.E.
        • Worrall C.
        • Kelman J.A.
        Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation.
        Circulation. 2015; 131: 157-164
        • Bai Y.
        • Deng H.
        • Shantsila A.
        • Lip G.Y.H.
        Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis.
        Stroke. 2017; 48: 970-976
        • Gong I.Y.
        • Kim R.B.
        Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
        Can J Cardiol. 2013; 29: S24-S33
        • Hernandez I.
        • Smith K.J.
        • Zhang Y.
        Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
        Thromb Res. 2017; 150: 123-130
        • Lip G.Y.
        • Keshishian A.
        • Kamble S.
        • Pan X.
        • Mardekian J.
        • Horblyuk R.
        • Hamilton M.
        Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
        Thromb Haemost. 2016; 116: 975-986
        • Lamberts M.
        • Staerk L.
        • Olesen J.B.
        • Fosbol E.L.
        • Hansen M.L.
        • Harboe L.
        • Lefevre C.
        • Evans D.
        • Gislason G.H.
        Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients.
        J Am Heart Assoc. 2017; 6: e004517
        • Food and Drug Administration
        Prescribing information for Xarelto.
        (Available at:)
        • Food and Drug Administration
        Pradaxa prescribing information.
        (Available at:)
        • Fink J.L.W.
        FDA panel votes for rivaroxaban (Xarelto): atrial fibrillation patients may soon have two alternatives to warfarin for stroke prevention.
        (Available at:)
        • Brown J.D.
        • Shewale A.R.
        • Talbert J.C.
        Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naive nonvalvular atrial fibrillation.
        J Manag Care Spec Pharm. 2016; 22: 1319-1329
        • Johnson M.E.
        • Lefevre C.
        • Collings S.L.
        • Evans D.
        • Kloss S.
        • Ridha E.
        • Maguire A.
        Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care.
        BMJ Open. 2016; 6: e011471
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.
        • Lopes R.D.
        • Hylek E.M.
        • Hanna M.
        • Al-Khalidi H.R.
        • Ansell J.
        • Atar D.
        • Avezum A.
        • Bahit M.C.
        • Diaz R.
        • Easton J.D.
        • Ezekowitz J.A.
        • Flaker G.
        • Garcia D.
        • Geraldes M.
        • Gersh B.J.
        • Golitsyn S.
        • Goto S.
        • Hermosillo A.G.
        • Hohnloser S.H.
        • Horowitz J.
        • Mohan P.
        • Jansky P.
        • Lewis B.S.
        • Lopez-Sendon J.L.
        • Pais P.
        • Parkhomenko A.
        • Verheugt F.W.
        • Zhu J.
        • Wallentin L.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • Eikelboom J.
        • Oldgren J.
        • Parekh A.
        • Pogue J.
        • Reilly P.A.
        • Themeles E.
        • Varrone J.
        • Wang S.
        • Alings M.
        • Xavier D.
        • Zhu J.
        • Diaz R.
        • Lewis B.S.
        • Darius H.
        • Diener H.-C.
        • Joyner C.D.
        • Wallentin L.
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Food and Drug Administration
        Prescribing information for Praxbind.
        (Available at:)
        • Connolly S.J.
        • Milling Jr, T.J.
        • Eikelboom J.W.
        • Gibson C.M.
        • Curnutte J.T.
        • Gold A.
        • Bronson M.D.
        • Lu G.
        • Conley P.B.
        • Verhamme P.
        • Schmidt J.
        • Middeldorp S.
        • Cohen A.T.
        • Beyer-Westendorf J.
        • Albaladejo P.
        • Lopez-Sendon J.
        • Goodman S.
        • Leeds J.
        • Wiens B.L.
        • Siegal D.M.
        • Zotova E.
        • Meeks B.
        • Nakamya J.
        • Lim W.T.
        • Crowther M.
        Andexanet alfa for acute major bleeding associated with factor Xa inhibitors.
        N Engl J Med. 2016; 375: 1131-1141